Skip to content
Adam Torkildson – Lifestyle
Author:
Relmada Therapeutics
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
March 9, 2026
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
March 9, 2026
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
March 9, 2026
←
Previous Page
1
2